On November 1, 2021 A2 Biotherapeutics, Inc., "A2 Bio", is a biotechnology company reported that focused on the development of first-in-class T cell therapies to treat solid tumors (Press release, A2 Biotherapeutics, NOV 1, 2021, View Source [SID1234594037]). A2 Bio will make two presentations at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting taking place virtually and in person on Nov. 10–14, 2021 at the Walter E. Washington Convention Center in Washington, D.C . The first presentation will focus on new preclinical in vitro and in vivo demonstrations of both CEA (A2B530) and MSLN (A2B694) Tmod T cell therapy. The second presentation will discuss an observational study, BASECAMP-1, to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future Tmod CAR T cell therapies (NCT#04981119).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to have been selected to present updates on our progress advancing the novel Tmod platform for the treatment of solid tumors, including supporting pre-clinical evidence for CEA (A2B530) and MSLN (A2B694) and an overview of our observational study BASECAMP-1 to identify patients that may benefit from future Tmod CAR T cell therapy," said Scott Foraker, chief executive officer at A2 Bio. "Our Tmod platform is a truly novel approach that has the potential to transform cancer treatment where current treatment approaches fall short, and we are working diligently to demonstrate this."
Julian Molina, MD, PhD, Professor of Oncology, Mayo Clinic, Rochester MN states, "BASECAMP-1 is a premier example of precision medicine. The goal is to identify incurable metastatic, unresectable locally advanced solid tumor patients that may benefit from future Tmod CAR T cell therapy. The pre-clinical Tmod CAR T cell therapy data is promising and we hope to translate this technology from bench to bedside to offer patients a potential treatment for solid tumors."
The two abstracts accepted for poster presentation at SITC (Free SITC Whitepaper) 2021 are:
Title: A powerful, precise targeting system controlled by tumor deletions transforms CEA and MSLN CAR-T cells into tumor-selective agents
Presenter: Alexander Kamb, PhD
Session: Poster
Date/Time: Saturday, November 13 at 7:00 am to 8:30 pm ET
Location: Hall E, Abstract 122
Title: BASECAMP-1: An observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T cell therapy
Presenter: Julian Molina, MD, PhD, Professor of Oncology, Mayo Clinic, Rochester MN
Session: Poster
Date/Time: Friday, November 12 at 7:00 am to 8:30 pm ET
Location: Hall E, Abstract 491